Afrezza gets FDA approval to boost glycemic control in adults with diabetes mellitus The U.S. Meals and Medication Administration today accepted Afrezza Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus. Afrezza is a rapid-performing inhaled insulin that’s administered at the beginning of every meal, or within 20 minutes after starting meals. Around 25.8 million people in the usa or around 8. Over time, high blood sugar can raise the risk for critical complications, including heart disease, blindness and nerve and kidney damage. Afrezza is a fresh treatment option for patients with diabetes requiring mealtime insulin, stated Jean-Marc Guettier, M.D., director of the Division of Fat burning capacity and Endocrinology Products in the FDA's Center for Drug Evaluation and Research.Michael, executive vice president, Diagnostics Products, Abbott. STARLIMS’ advanced web-based technologies might help our customers operate efficiently across the core laboratory, molecular and point-of care segments of the global diagnostics market. Healthcare informatics is the application of information management and technology to the look and delivery of top quality and cost-effective health care.Advanced informatics systems have become increasingly important to medical laboratories as a way to automate the retrieval, management and conversation of medical and laboratory data and help compliance with global regulatory and industry standards.